Anticancer Treatments and Cardiotoxicity

Patricio Lancellotti is head of the intensive care cardiology unit at the University of Liège Hospital Center and Professor of Clinical Medicine at the University of Liège. His research, conducted at Professor Luc Piérard's department of cardiology, has led to significant progress in the care of patients suffering from functional mitral insufficiency, a pathology often underestimated clinically yet weighing heavily on the prognosis. He has 300 peer-reviewed articles and an H-index = 40. José Luis Zamorano is Professor of Medicine and Head of Cardiology at the University Complutense in Madrid and Director of the Cardiovascular Institute at the University Clinic San Carlos, Madrid. His key research interests include ischemic heart disease, cardiovascular risk factors and imaging modalities. Professor Zamorano is President Elect of the European Association of Echocardiography (EAE) and President of the Working Group on Non-invasive Diagnostic Imaging of the Spanish Society of Cardiology. He serves on numerous Editorial Boards, including the European Journal of Echocardiography, the American Society of Echocardiography and the European Heart Journal. He has authored over 400 articles for peer-reviewed journals and has an H-index = 57. Maurizio Galderisi, is Associate Professor of Cardiology and Clinical Director at Federico II University Hospital in Italy. His research interests include cardiac function, heart failure, arterial hypertension, tissue Doppler and strain rate imaging, coronary flow reserve. He has served as editor of one book and author of 10 chapters in various cardiologic books. He is the author or co-author of 250 articles on international peer-reviewed indexed journals, with an H-index = 38. He has been an invited speaker at more than 70 major national and international meetings and holds scientific association membership with Società Italiana di Cardiologia (SIC), Società Italiana di Ecografia Cardiovascolare (SIEC), European Association of Echocardiography (EAE), and the American Society of Echocardiography (ASE).

Section I: General Considerations
1. Epidemiology and Trend of Prognosis in Cancer Patients
2. Categories of Anticancer Treatments
3. Classification by Mechanisms of Cardiotoxicity
4. Cardiotoxicity of Oncologic Treatments: Is There a Uniform Definition?
5. The Impact of Radiotherapy

Section II: Detrimental Effects of Anticancer Drugs and Radiotherapy on the Heart
6. Lessons From Preclinical Models
7. Genetic and Epigenetic Risk Factors
8. Changes of Myocardial Structure and Function
9. Alteration of Heart Valves
10. Pericardial Damage
11. Effects of Radiotherapy on Vessels and Coronary Arteries
12. Cardiac Conduction Disturbances

Section III: Cardiovascular Complications of Cancer Treatments
13. Cardiac Rhythm Disturbances
14. Acute and Chronic Heart Failure
15. Coronary Artery Disease
16. Pericardial Effusion and Pericarditis
17. Radiation-Induced Carotid Atherosclerosis
18. Valvular Heart Disease
19. Atrial Fibrillation and Stroke in Cancer Patients

Section IV: Imaging Evaluation of Cardiac Structure and Function in Cancer Patients
20. The Role of Echocardiography
21. The Role of Cardiovascular Magnetic Resonance (CMR)
22. Nuclear Medicine Imaging and Cardiotoxicity

Section V: Detection of Cardiac Dysfunction and Predictors of Cardiotoxicity
23. Detection by Cardiac Imaging: LV Ejection Fraction, Diastolic Dysfunction, Tissue Doppler, and Speckle Tracking Echocardiography
24. The Role of Biomarkers: Troponins, BNP, MPO, and Other Biomarkers
25. Screening and Comprehensive Follow-Up Evaluation
26. Preoperative Assessment for Noncardiac Surgery

Section VI: Cardiotoxicity in Childhood
27. Cardiotoxicity of Childhood Cancer Treatments

Section VII: Management of Anticancer Drugs Related Cardiotoxicity
28. Nonpharmacologic Therapy
29. Beta-Blockers
30. Angiotensin-Converting Enzyme Inhibition
31. Diuretics
32. Antiarrhythmic Drugs
33. Anticoagulation in Cancer Patients
34. New Drugs: The Beneficial Effects of Ranolazine
35. Percutaneous Coronary Intervention and Cardiac Surgery in Cancer Patients
36. Focus on the Patient With Known Cardiac Disease
37. Multidisciplinary Approach to Cardiac Disease in Cancer Patients

Section VIII: Future Research Priorities
38. Pharmacogenomics Screening
39. Cardiac Monitoring During Clinical Trials
40. Preventive Therapy
41. Cardiotoxicity: Future Research Directions